IBI 314
Alternative Names: Anti-COVID-2019 antibody - Innovent Biologics; IBI-314; IBI314-A/IBI314-BLatest Information Update: 28 Dec 2023
At a glance
- Originator Innovent Biologics
- Class Antibodies; Antivirals
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 18 Dec 2023 Discontinued - Phase-I/II for COVID-2019 infections (In the elderly, In adults) in China (IV)
- 18 Dec 2023 Discontinued - Phase-I/II for COVID-2019 infections (In the elderly, In adults) in USA (IV)
- 18 Dec 2023 Innovent Biologics terminates a phase I/II trial in COVID-2019 infections (In adults, In the elderly) in the USA (IV) due to the company's decision to terminate the further development of the molecule (NCT05162365)